Article
Rheumatology
Paul Studenic, Daniel Aletaha, Maarten de Wit, Tanja A. Stamm, Farideh Alasti, Diane Lacaille, Josef S. Smolen, David T. Felson
Summary: This study aimed to externally validate a revised Boolean remission criteria using a higher patient global assessment (PtGA) threshold and validate the provisionally endorsed index-based criteria. The results showed that using the higher PtGA threshold increased the proportion of patients classified as achieving remission under the "Boolean2.0" criteria, improved agreement with index-based criteria, and did not compromise predictive value for radiographic or functional outcomes. The study findings were endorsed by ACR and EULAR.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Claire Daien, Marek Krogulec, Paul Gineste, Jean-Marc Steens, Laurence Desroys du Roure, Sophie Biguenet, Didier Scherrer, Julien Santo, Hartmut Ehrlich, Patrick Durez
Summary: This study evaluated the safety and efficacy of ABX464 in patients with moderate-to-severe active rheumatoid arthritis. The results showed that ABX464 at a 50 mg dose was safe, well tolerated, and showed promising efficacy. The 100 mg dose had a high dropout rate due to gastrointestinal adverse events.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Endocrinology & Metabolism
D. P. Destiani, S. Naja, S. Dewi, A. R. Rahmadi, S. A. S. Sulaiman, R. Abdulah
Summary: Methotrexate (MTX) remains commonly used for the management of rheumatoid arthritis (RA) despite the development of new drugs. A systematic review of MTX effectiveness in reducing bone erosion risk was presented in this article, with key factors such as gene polymorphism influencing treatment response. Future investigations are needed to clarify the exact mechanism of MTX in preventing bone erosion.
OSTEOPOROSIS INTERNATIONAL
(2021)
Review
Pharmacology & Pharmacy
Yuehong Chen, Huan Liu, Yunru Tian, Zhongling Luo, Geng Yin, Qibing Xie
Summary: This study assessed the neoplasm risk in rheumatoid arthritis patients treated with fostamatinib and found that fostamatinib is not associated with overall neoplasm risk compared to placebo. However, long-term use may be associated with a risk of malignant neoplasms, and higher doses of fostamatinib may increase the risk of malignant neoplasms in the digestive system.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Kayalvizhi Rajendran, Suman Pahal, Kedar Badnikar, Manjunatha M. Nayak, Dinesh N. Subramanyam, Praveen K. Vemula, Uma Maheswari Krishnan
Summary: Arthritis is an inflammatory disorder that severely affects mobility. Existing treatments have limited effectiveness, and lack of adherence to therapeutic regimen worsens the condition. This study develops a microneedle patch that allows sustained release of an anti-arthritic drug at the site of inflammation, leading to faster restoration of mobility and reduction in inflammatory markers. The results demonstrate the potential of microneedle-based platform for effective arthritic therapy.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Pharmacology & Pharmacy
Weiman Zhao, Lijie Zheng, Jianhui Yang, Zihui Ma, Xinyi Tao, Qingqing Wang
Summary: This study developed a dissolving microneedle patch (DMNP) for transdermal delivery of methotrexate (MTX) to treat rheumatoid arthritis (RA). The DMNP demonstrated excellent morphology and mechanical strength, and significantly increased the transdermal permeation of MTX compared to cream. In vivo experiments showed that MTX-loaded DMNP effectively alleviated RA symptoms and inhibited inflammatory response. This transdermal drug delivery system has the potential to improve the safety, convenience, and efficacy of MTX treatment for RA.
Article
Rheumatology
Renske C. F. Hebing, Marry Lin, Maja Bulatovic Calasan, Ittai B. Muller, Sohaila Mahmoud, Sandra Heil, Eduard A. Struys, Bart J. F. van den Bemt, Jos W. R. Twisk, Willem Lems, Michael T. Nurmohamed, Gerrit Jansen, Robert de Jonge
Summary: This study investigates the pharmacokinetics of methotrexate polyglutamate (MTX-PG) accumulation in red blood cells (RBCs) and peripheral blood mononuclear cells (PBMCs) in patients with early rheumatoid arthritis (RA) after oral and subcutaneous MTX treatment. The results show that there are disparate pharmacokinetic profiles between PBMCs and RBCs, with higher accumulation of MTX-PG in PBMCs. The distribution profile of MTX-PG in PBMCs remains constant over 6 months, while in RBCs, the main PG-moiety changes from MTX-PG(1) to MTX-PG(3).
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Delila Singh, Nina Hesse, Alla Skapenko, Hendrik Schulze-Koops
Summary: Methotrexate is associated with rare bone lesions that are often misdiagnosed as osteoporotic fractures. Early diagnosis is crucial for treatment and prevention of further osteopathology. This case highlights the importance of raising awareness and taking appropriate therapeutic measures, including discontinuing methotrexate.
Article
Chemistry, Analytical
Junqing He, Junyan Wang, Min Zhang, Guoyue Shi
Summary: As a folate antagonist, methotrexate (MTX) has been widely used in clinics for treating various tumors and inflammatory diseases. However, the dosage and clearance of MTX vary between individuals, and it may cause life-threatening side effects at high doses. Therefore, a convenient and simple method for MTX sensing is highly demanded.
Article
Rheumatology
Clement Triaille, Gaelle Tilman, Tatiana Sokolova, Axelle Loriot, Joelle Marchandise, Stephanie De Montjoye, Adrien Nzeusseu-Toukap, Laurent Meric de Bellefon, Caroline Bouzin, Christine Galant, Patrick Durez, Bernard R. Lauwerys, Nisha Limaye
Summary: This study used transcriptomic profiling to explore clinically relevant subgroups in early, untreated rheumatoid arthritis (RA) patients. The synovial transcriptome closely mirrored clinical disease activity, and the ratio of M2:M1 macrophages was inversely correlated with inflammation and disease activity, suggesting a protective role for tissue resident macrophages in RA.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Biochemistry & Molecular Biology
Matthew R. Medcalf, Pooja Bhadbhade, Ted R. Mikuls, James R. O'Dell, Rebekah L. Gundry, Ryan S. Funk
Summary: The study found that RA patients have altered plasma metabolome which is partially normalized following initiation of MTX therapy. Different metabolites were found to be impacted in responders and non-responders to MTX therapy.
Review
Pharmacology & Pharmacy
Yuehong Chen, Huan Liu, Yupeng Huang, Sang Lin, Geng Yin, Qibing Xie
Summary: This study found that patients with RA treated with fostamatinib had an increased risk of hypertension compared to placebo, but no increased risk of cardiovascular events. Sensitivity analysis showed robust results with no publication bias.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Rheumatology
Siddharth Jain, Varun Dhir, Amita Aggarwal, Ranjan Gupta, Bidyalaxmi Leishangthem, Shankar Naidu, Aastha Khullar, Supriya Maurya, Veena Dhawan, Shefali Khanna Sharma, Aman Sharma, Sanjay Jain
Summary: This study compared the efficacy and safety of different dose escalation strategies of oral MTX in RA patients over a period of 16-24 weeks. The results showed that a faster escalation strategy was not more effective than the usual strategy, but was associated with higher gastrointestinal adverse events in the initial phase.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Multidisciplinary Sciences
Helen R. Gosselt, Costanza L. Vallerga, Pooja R. Mandaviya, Erik Lubberts, Johanna M. W. Hazes, Robert de Jonge, Sandra G. Heil
Summary: The study did not identify genome-wide significant differences as biomarkers for Methotrexate (MTX) therapy response, necessitating meta-analyses.
Article
Rheumatology
Ulf Lindstrom, Daniela di Giuseppe, Sofia Exarchou, Gerd-Marie Alenius, Tor Olofsson, Eva Klingberg, Lennart Jacobsson, Johan Askling, Johan K. Wallman
Summary: This study aimed to compare the treatment outcomes of patients with newly diagnosed psoriatic arthritis (PsA) and rheumatoid arthritis (RA) using methotrexate (MTX) monotherapy. The results showed that PsA patients were less likely to continue the use of MTX compared to RA patients, and the effectiveness of MTX was also lower in PsA.
Letter
Rheumatology
Anna Molto, Desiree van der Heijde, Filip E. van den Bosch, Maxime Dougados
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Ricardo J. O. Ferreira, Paco M. J. Welsing, Johannes W. G. Jacobs, Laure Gossec, Mwidimi Ndosi, Pedro M. Machado, Desiree van der Heijde, Jose A. P. Da Silva
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Casper Webers, Augusta Ortolan, Alexandre Sepriano, Louise Falzon, Xenofon Baraliakos, Robert B. M. Landewe, Sofia Ramiro, Desiree van der Heijde, Elena Nikiphorou
Summary: This study aims to provide updated evidence on the efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) for the revision of management recommendations. The results showed significant efficacy of tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i), while IL-23 inhibitors failed to demonstrate relevant effects. Observational studies are required to confirm the long-term safety of IL-17i.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Augusta Ortolan, Casper Webers, Alexandre Sepriano, Louise Falzon, Xenofon Baraliakos, Robert B. M. Landewe, Sofia Ramiro, Desiree van der Heijde, Elena Nikiphorou
Summary: This study updated the evidence of non-biological treatments for axSpA, providing a basis for the 2022 ASAS-EULAR recommendations. The results showed that education, exercise, and NSAIDs were efficacious in axSpA.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Desiree van der Heijde, Atul Deodhar, Xenofon Baraliakos, Matthew A. Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, Alicia M. Ellis, Carmen Fleurinck, Karl Gaffney, Lianne S. Gensler, Nigil Haroon, Marina Magrey, Walter P. Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martin Rudwaleit, Julie Shepherd-Smith, Tetsuya Tomita, Filip van den Bosch, Thomas Vaux, Huji Xu
Summary: The BE MOBILE 1 and BE MOBILE 2 trials demonstrated that bimekizumab, a dual IL-17A and IL-17F inhibitor, improved efficacy outcomes in patients with axial spondyloarthritis (axSpA) and was well tolerated. These findings support the use of bimekizumab as a potential treatment option for axSpA.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Andreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Robert B. M. Landewe
Summary: This study aimed to update the evidence on the efficacy of DMARDs and provide information for the 2022 update of EULAR recommendations for RA management. A systematic literature review was conducted to investigate the efficacy of cs, b, biosimilar, and tsDMARDs in RA patients. The results showed that csDMARDs combined with short-term glucocorticoids in early RA were as effective as bDMARD+MTX combination therapy. JAK inhibitors were effective in different patient populations. Tapering of DMARDs was feasible for some patients who could maintain low disease activity or achieve remission.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher J. Edwards, Patrick Verschueren, Savia de Souza, Janet Pope, Tsutomu Takeuchi, Kimme Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja Stamm, Jan W. Schoones, Robert B. M. Landewe
Summary: This study conducted a systematic literature review (SLR) to evaluate the safety of synthetic and biological disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA). The results indicated that bDMARDs were associated with an increased risk of serious infections compared to csDMARDs, while JAK inhibitors (JAKi) showed higher risk of herpes zoster infections. The risks of malignancies, major adverse cardiovascular events (MACE), and venous thromboembolism (VTE) were similar among different treatments.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Sytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Josef S. Smolen, Robert B. M. Landewe
Summary: This systematic literature review examines the efficacy, duration of use, and safety of glucocorticoids (GCs) in the management of rheumatoid arthritis (RA). The study confirms the effectiveness of GCs in treating RA, with most patients able to stop GCs within 12-24 months. However, the use of GCs also carries well-known safety risks, including osteoporotic fractures, serious infections, diabetes, and mortality.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Sofia Ramiro, Robert Landewe, Desiree van der Heijde, Alexandre Sepriano, Oliver FitzGerald, Mikkel Ostergaard, Joanne Homik, Ori Elkayam, J. Carter Thorne, Maggie J. Larche, Gianfranco Ferraccioli, Marina Backhaus, Gilles Boire, Bernard Combe, Thierry Schaeverbeke, Alain Saraux, Maxime Dougados, Maurizio Rossini, Marcello Govoni, Luigi Sinigaglia, Alain G. Cantagrel, Cornelia F. Allaart, Cheryl Barnabe, Clifton O. Bingham III, Dirkjan van Schaardenburg, Hilde B. Hammer, Rana Dadashova, Edna Hutchings, Joel Paschke, Walter P. Maksymowych
Summary: The study investigates whether meticulously following a treat-to-target (T2T) strategy in daily clinical practice leads to less radiographic progression in patients with active rheumatoid arthritis (RA). The findings show that a more stringent application of T2T does not result in less radiographic progression compared to a somewhat lenient attitude towards T2T.
Correction
Rheumatology
Atul Deodhar, Denis Poddubnyy, Proton Rahman, Jeorg Ermann, Tetsuya Tomita, Rebeca Bolce, Soyi Liu Leage, Andris Kronbergs, Caroline Johnson, Joana Araujo, Ann Leung, Desiree van der Heijde
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Rosalinde Stal, Sofia Ramiro, Xenofon Baraliakos, Juergen Braun, Monique Reijnierse, Rosaline van den Berg, Desiree van der Heijde, Floris A. van Gaalen
Summary: The objective of this study was to assess the construct validity of the CT Syndesmophyte Score (CTSS) for measuring structural spinal damage in patients with radiographic axial spondyloarthritis. The study compared the scores of CTSS and modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) in detecting syndesmophytes and their correlation with spinal mobility. The results demonstrated good agreement between CTSS and mSASSS in detecting syndesmophytes, and higher correlation of CTSS with spinal mobility measures.
Article
Rheumatology
Mary Lucy Marques, Nuno Pereira da Silva, Desiree van der Heijde, Rosalinde Stal, Xenofon Baraliakos, Juergen Braun, Monique Reijnierse, Caroline Bastiaenen, Sofia Ramiro, Floris A. van Gaalen
Summary: The study investigated the association between inflammation and lower trabecular bone density (TBD) in radiographic axial spondyloarthritis (r-axSpA), and whether a lower TBD increases the likelihood of 2-year bone formation at the same vertebra. The study found that inflammation was associated with lower TBD, but lower TBD itself did not increase the risk of new bone formation at the same vertebra.
Article
Rheumatology
Robert Landewe, Luna Sun, Yun-Fei Chen, Daojun Mo, Desiree van der Heijde
Summary: Demonstrating the inhibition of joint damage in rheumatoid arthritis trials is commonly achieved through statistically significant differences in radiographic progression measured by the mTSS. The frequently used ANCOVA+LE method for handling missing data may not be ideal for long-term extension or paediatric studies. The RC model shows better performance in terms of bias, RMSE, power and type I error rate, making it a more sensitive and precise alternative for analysing mTSS in studies with missing data.
Article
Rheumatology
Rosalinde Stal, Sofia Ramiro, Desiree van der Heijde, Floris A. van Gaalen, Xenofon Baraliakos, Pedro M. Machado, Manouk de Hooge, Rosaline van den Berg, Monique Reijnierse, Juergen Braun, Robert Landewe, Alexandre Sepriano
Summary: In patients with radiographic axial spondyloarthritis, vertebral corner inflammation can lead to the development of syndesmophytes, but only a small portion of this effect is explained by vertebral corner fat deposition.
Letter
Rheumatology
Valeriia Melokhina, Nina Paulshus Sundlisaeter, Joseph Sexton, Ulf Sundin, Anna-Birgitte Aga, Kaja E. Kjorholt, Lena Bugge Nordberg, Desiree van der Heijde, Espen Haavardsholm, Siri Lillegraven
ANNALS OF THE RHEUMATIC DISEASES
(2023)